Efficacy and safety of evolocumab in Chinese patients with primary hypercholesterolemia and mixed dyslipidemia: 12-week primary results of the HUA TUO 华佗 randomized clinical trialed Item
mediaposted on 2023-02-03, 09:10 authored by Adis journals on behalf of, Jiyan Chen, Hong Tan, Weimin Li, Zhouqing Huang, Yajun Han, Xuecheng Huang, Dongye Li, Xiaochun Xing, Maria Laura Monsalvo, You Wu, Jackie Mao, Lily Xin
The above graphical abstract and the Chinese and Japanese translations of the abstract represent the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. (see “read the peer-reviewed publication” opposite).